Bulletin
Investor Alert

press release

Sept. 8, 2021, 8:05 a.m. EDT

Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

GAINESVILLE, Fla., (BUSINESS WIRE) -- Cyclo Therapeutics, Inc. /zigman2/quotes/207006339/composite CYTH +1.68% (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the virtual H.C. Wainwright 23 [rd] Annual Global Investment Conference taking place September 13-15, 2021.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website .

A video webcast of the presentation will be available for viewing on-demand beginning on Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website ( www.cyclotherapeutics.com ). The webcast replay will be archived for 90 days following the event.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol [®] Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, ( www.ClinicalTrials.gov NCT02939547 , NCT02912793 , NCT03893071 and NCT04860960 ). The Company is planning an early phase clinical trial using Trappsol [®] Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease ( NCT03624842 ). Additional indications for the active ingredient in Trappsol [®] Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005214/en/

SOURCE: Cyclo Therapeutics, Inc.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
CYTH@jtcir.com

COMTEX_392975338/2456/2021-09-08T08:05:13

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2021

/zigman2/quotes/207006339/composite
US : U.S.: Nasdaq
$ 3.63
+0.06 +1.68%
Volume: 30,264
Jan. 28, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$30.01 million
Rev. per Employee
$143,278
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.